Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)
February 25 2019 - 6:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
Spark Therapeutics, Inc.
(Name of Subject Company)
Spark
Therapeutics, Inc.
(Name of Persons Filing Statement)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
84652J103
(CUSIP Number
of Class of Securities)
Jeffrey D. Marrazzo
Chief Executive Officer
3737 Market Street
Philadelphia, PA 19104
(Name, Address and Telephone Number, including area code, of Agent For Service)
With copies to:
Stuart M. Cable, Esq.
Lisa R. Haddad, Esq.
Blake Liggio, Esq.
Goodwin Procter LLP
100
Northern Avenue
Boston, MA 02210
(617) 570-1000
(Name,
address, and telephone numbers of person authorized to receive notices and communications
on behalf of the persons filing statement)
|
☒
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a
tender offer.
|
The information set forth under Items 1.01, 5.03, 7.01 and 9.01 of the Current Report on Form 8-K filed by Spark
Therapeutics, Inc. on February 25, 2019 (including all exhibits attached thereto) is incorporated herein by reference.
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Feb 2025 to Mar 2025
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Mar 2024 to Mar 2025
